These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23215719)

  • 1. The PI3 kinase signaling pathway in prostate cancer.
    Elfiky AA; Jiang Z
    Curr Cancer Drug Targets; 2013 Feb; 13(2):157-64. PubMed ID: 23215719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
    Sarker D; Reid AH; Yap TA; de Bono JS
    Clin Cancer Res; 2009 Aug; 15(15):4799-805. PubMed ID: 19638457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
    Kadowaki Y; Chari NS; Teo AE; Hashi A; Spurgers KB; McDonnell TJ
    Apoptosis; 2011 Jun; 16(6):627-35. PubMed ID: 21437722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
    Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
    Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.
    Pommery N; Hénichart JP
    Mini Rev Med Chem; 2005 Dec; 5(12):1125-32. PubMed ID: 16375758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).
    Toren P; Zoubeidi A
    Int J Oncol; 2014 Nov; 45(5):1793-801. PubMed ID: 25120209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q; Lui VW; Yeo W
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
    Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
    Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
    Lee TJ; Sartor O; Luftig RB; Koochekpour S
    Mol Cancer; 2004 Nov; 3():31. PubMed ID: 15548330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K pathway in prostate cancer: All resistant roads lead to PI3K.
    Park S; Kim YS; Kim DY; So I; Jeon JH
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):198-206. PubMed ID: 30300679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
    Li L; Ittmann MM; Ayala G; Tsai MJ; Amato RJ; Wheeler TM; Miles BJ; Kadmon D; Thompson TC
    Prostate Cancer Prostatic Dis; 2005; 8(2):108-18. PubMed ID: 15724144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C; Fizazi K
    Clin Cancer Res; 2011 Jun; 17(12):3876-83. PubMed ID: 21680543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
    Georgi B; Korzeniewski N; Hadaschik B; Grüllich C; Roth W; Sültmann H; Pahernik S; Hohenfellner M; Duensing S
    Int J Oncol; 2014 Oct; 45(4):1337-44. PubMed ID: 25070358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells.
    Yang L; Wang L; Lin HK; Kan PY; Xie S; Tsai MY; Wang PH; Chen YT; Chang C
    Biochem Biophys Res Commun; 2003 Jun; 305(3):462-9. PubMed ID: 12763015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
    Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ
    Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
    Pang J; Yang YW; Huang Y; Yang J; Zhang H; Chen R; Dong L; Huang Y; Wang D; Liu J; Li B
    Prostate; 2017 Feb; 77(3):299-308. PubMed ID: 27800642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.